---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-25-000086"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:12:51.857803+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xencor narrows Q3 net loss to $6M; advances key bispecific antibodies toward pivotal studies

## Summary
- Net loss $6.0M ($0.08 per share) vs $46.3M loss ($0.72) in Q3 2024; revenue $21.0M, up from $17.8M.
- Cash $633.9M at Sept 30, 2025; expects year-end cash $570-590M and runway into 2028.
- XmAb819 (ccRCC) and XmAb541 (gynecologic/germ cell) show early PRs; Phase 3 dose selection in 2026; pivotal studies targeted for 2027.
- First patient dosed in plamotamab Phase 1b RA study; XmAb942 Phase 2b XENITH-UC enrolling; XmAb657 and XmAb412 studies on track.
- Partners advancing: Amgen Phase 3 XALience for xaluritamig; Astellas data on ASP2138; Zenas positive Phase 2 in MS.

## SEC filing metadata
- accession: 0001326732-25-000086
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673225000086/0001326732-25-000086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673225000086/xncr-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-25-000086
- JSON: https://secwatch.observer/filing/0001326732-25-000086.json
- Plain text: https://secwatch.observer/filing/0001326732-25-000086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.